T. Rowe Price Associates’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$3.14M Buy
271,078
+19,814
+8% +$230K ﹤0.01% 1456
2025
Q1
$2.2M Sell
251,264
-1,530,004
-86% -$13.4M ﹤0.01% 1565
2024
Q4
$25.6M Sell
1,781,268
-734,635
-29% -$10.5M ﹤0.01% 927
2024
Q3
$56.8M Sell
2,515,903
-358,049
-12% -$8.08M 0.01% 716
2024
Q2
$55.9M Sell
2,873,952
-783,275
-21% -$15.2M 0.01% 685
2024
Q1
$137M Buy
3,657,227
+553,053
+18% +$20.8M 0.02% 491
2023
Q4
$174M Buy
3,104,174
+416,723
+16% +$23.3M 0.02% 436
2023
Q3
$111M Buy
2,687,451
+30,127
+1% +$1.24M 0.02% 493
2023
Q2
$148M Buy
2,657,324
+243,364
+10% +$13.6M 0.02% 443
2023
Q1
$135M Buy
2,413,960
+401,785
+20% +$22.4M 0.02% 465
2022
Q4
$73.3M Sell
2,012,175
-337,054
-14% -$12.3M 0.01% 561
2022
Q3
$66.9M Buy
2,349,229
+1,010,643
+76% +$28.8M 0.01% 572
2022
Q2
$60.6M Buy
1,338,586
+187,833
+16% +$8.5M 0.01% 822
2022
Q1
$87.5M Buy
1,150,753
+73,541
+7% +$5.59M 0.01% 773
2021
Q4
$160M Buy
1,077,212
+105,195
+11% +$15.7M 0.01% 616
2021
Q3
$142M Sell
972,017
-92,621
-9% -$13.5M 0.01% 659
2021
Q2
$208M Buy
1,064,638
+233,535
+28% +$45.7M 0.02% 544
2021
Q1
$150M Sell
831,103
-25,183
-3% -$4.56M 0.02% 640
2020
Q4
$121M Buy
856,286
+177,172
+26% +$25.1M 0.01% 670
2020
Q3
$84.7M Buy
679,114
+289,604
+74% +$36.1M 0.01% 709
2020
Q2
$34.8M Buy
389,510
+44,616
+13% +$3.98M ﹤0.01% 974
2020
Q1
$21.5M Buy
344,894
+160,810
+87% +$10M ﹤0.01% 1046
2019
Q4
$14M Sell
184,084
-497,316
-73% -$37.9M ﹤0.01% 1255
2019
Q3
$34.3M Buy
+681,400
New +$34.3M ﹤0.01% 989